Literature DB >> 31023612

Identification of genetic alterations in extramammary Paget disease using whole exome analysis.

Yukiko Kiniwa1, Jun Yasuda2, Sakae Saito3, Rumiko Saito3, Ikuko N Motoike4, Inaho Danjoh3, Kengo Kinoshita5, Nobuo Fuse3, Masayuki Yamamoto6, Ryuhei Okuyama7.   

Abstract

BACKGROUND: Extramammary Paget disease (EMPD) is a rare cutaneous malignant neoplasm, and the genomic alterations underlying its pathogenesis are unknown.
OBJECTIVE: To identify tumor-specific genomic alterations in EMPD.
METHODS: Exome analysis was performed in specimens from three EMPD patients, and target amplicon sequencing was done for genes frequently mutated in other adenocarcinomas.
RESULTS: Exome analysis revealed recurrent somatic mutations in several genes, includingTP53, PIK3CA, and ERBB2. We identified additional candidate exons by searching the COSMIC database for exons that are frequently mutated in other adenocarcinomas. We obtained 19 exons in 12 genes as candidate exons, and performed target amplicon sequencing in samples obtained from EMPD patients. New somatic mutations in the TP53 gene were identified in six EMPD patients. Single nucleotide polymorphism analysis revealed multiple chromosomal alterations in three EMPD specimens, and two specimens exhibited amplification of chromosome 12p13 and losses of 3p21-24, 7q22 and 13q12-21.
CONCLUSION: Our comprehensive genetic analysis identified novel genomic alterations, and will inform treatment options for EMPD.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chromosomal copy number alteration; ERBB2; Exome; Extramammary Paget disease; PIK3CA; TP53

Year:  2019        PMID: 31023612     DOI: 10.1016/j.jdermsci.2019.03.006

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  7 in total

Review 1.  [Extramammary Paget's disease].

Authors:  I Cosgarea; A Zaremba; U Hillen
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

2.  Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature.

Authors:  Xin Yin; Xiaoqing Li; Muli Li; Qing She; Yan Liu; Xiaodan Chen; Suhua Ma; Qian Ma; Zhangkan Huang; Lin Xu; Xiaozhun Huang; Zhengyin Zhan; Xu Che
Journal:  Front Med (Lausanne)       Date:  2022-05-24

3.  Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva.

Authors:  Marina Stasenko; Gowtham Jayakumaran; Renee Cowan; Vance Broach; Dennis S Chi; Anthony Rossi; Travis J Hollman; Ahmet Zehir; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  JCO Precis Oncol       Date:  2020-09-15

4.  Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.

Authors:  Zoran Gatalica; Semir Vranic; Božo Krušlin; Kelsey Poorman; Phillip Stafford; Denisa Kacerovska; Wijendra Senarathne; Elena Florento; Elma Contreras; Alexandra Leary; April Choi; Gino K In
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

5.  Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.

Authors:  Shinya Kitamura; Teruki Yanagi; Takuya Maeda; Hideyuki Ujiie
Journal:  Cancer Sci       Date:  2021-12-13       Impact factor: 6.716

6.  Cell origin and genome profile difference of penoscrotum invasive extramammary Paget disease compared with its in situ counterpart.

Authors:  Yamin Rao; Jinchao Zhu; Haiyan Zheng; Yong Ren; Tianhai Ji
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

7.  Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.

Authors:  Takuya Takeichi; Yusuke Okuno; Takaaki Matsumoto; Nobuyuki Tsunoda; Kyogo Suzuki; Kana Tanahashi; Michihiro Kono; Toyone Kikumori; Yoshinao Muro; Masashi Akiyama
Journal:  Cancers (Basel)       Date:  2020-03-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.